FMC (NYSE:FMC) 2026 Conference February 25, 2026 02:45 PM ET Company ParticipantsAndrew Sandifer - EVP and CFOPierre Brondeau - Chairman, President, and CEOConference Call ParticipantsNone - AnalystNone - AnalystModeratorWelcome back, everybody. As we kind of move into the afternoon, I'm pleased to be welcoming Pierre Brondeau, CEO and President of FMC, and Andrew Sandifer, who's EVP and CFO. You know, FMC been a long-standing participant in the conference and obviously a very fundamentally important player ...

About FMC PHILADELPHIA, Feb. 23, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) announced that the Herbicide Resistance Action Committee (HRAC) has classified rimisoxafen as a dual mode of action herbicide, designated under HRAC Groups 12 and 32. This is the first dual mode of action classification in HRAC's history, a significant milestone for the global crop protection industry and validation of FMC's innovative approach to combating herbicide-resistant weeds. The unprecedented classification recognizes ...

Core Viewpoint - FMC Corporation's stock has significantly declined following poor Q3 earnings and continued challenges in Q4, leading to a cautious outlook for investors [1][2]. Financial Performance - Q3 earnings revealed a 49% drop in sales, resulting in a loss of $4.52 per share, and a full-year revenue decline of 18% in 2025 [1][5]. - Q4 earnings missed revenue expectations, with management forecasting a further 5% decline in revenue to approximately $3.7 billion in 2026 and a 41% decline in adjusted EBITDA [2][8]. Stock Performance - Since the Q3 earnings report, FMC stock has stabilized, trading between $13 and $17, currently priced around $14.50 [3][8]. - The market capitalization of FMC is approximately $1.8 billion, with a current price-to-free cash flow ratio of 30 times, indicating a potentially expensive valuation given the debt load [8][9]. Strategic Options - FMC is exploring strategic options to maximize shareholder value, including the potential sale of the company [6]. - The company plans to raise $1 billion through asset sales and licensing agreements to reduce its debt, which currently exceeds cash by $3.5 billion [6]. Product Development - FMC is set to commercialize four new herbicides and fungicides, which may contribute to future revenue growth [7].

Core Insights - FMC Corporation announced its 2026 operational priorities, focusing on strengthening its balance sheet and exploring strategic options to enhance shareholder value [2][3][5] Financial Performance - For the fourth quarter of 2025, FMC reported revenue of $1.08 billion, a decline of 12% compared to the fourth quarter of 2024, with a 6% price decline primarily due to Rynaxypyr® [13][14] - The full year 2025 revenue was $3.47 billion, an 18% decrease from 2024, driven by a 6% price decline and competitive pressures [16][17] - Adjusted EBITDA for 2025 was $843 million, down 7% year-over-year, with favorable costs offset by price declines and the removal of India sales [18] 2026 Outlook - FMC's revenue guidance for 2026 is projected between $3.60 billion and $3.80 billion, reflecting a 5% decline at the midpoint compared to the previous year [6] - Adjusted EBITDA for 2026 is expected to be between $670 million and $730 million, a 17% decrease from the prior year [7] - Adjusted EPS for 2026 is forecasted to be between $1.63 and $1.89, a decrease of 41% compared to the previous year [7] Strategic Initiatives - The company plans to pay down $1 billion in debt through asset sales and licensing agreements, including the sale of its India commercial business [3][4] - FMC aims to improve the competitiveness of its core portfolio and manage the post-patent transition for Rynaxypyr® while advancing the commercialization of new active ingredients [3][4] Market Dynamics - The anticipated decline in revenue is attributed to lower prices and reduced orders from diamide partners, with India representing a 2% headwind [6] - Sales of new active ingredients are expected to grow significantly, projected between $300 million and $400 million, marking over 75% growth at the midpoint compared to the previous year [6]